I. Olivotto

Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)

P. Seferovic, D. Jakovljevic, M. Tafelmeier, 2024, European journal of heart failure.

Anderson-Fabry disease management: role of the cardiologist.

Robert J. Desnick, M. Pieroni, Mehdi Namdar, 2024, European heart journal.

A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers

A. Saguner, H. Tandri, A. T. te Riele, 2024, European heart journal.

Clinical features and outcomes in carriers of pathogenic desmoplakin variants.

A. Saguner, H. Tandri, A. T. te Riele, 2024, European heart journal.

Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy.

V. Rella, G. Carrassa, M. Meda, 2024, International journal of cardiology.

Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population

C. Autore, G. Sinagra, F. Re, 2023, European journal of heart failure.

Cardiopulmonary Fitness and Personalized Exercise Prescription in Patients With Hypertrophic Cardiomyopathy.

M. Bonifazi, M. Focardi, G. Mandoli, 2024, Journal of the American Heart Association.